Search 

Fat and muscle measurement for the obesity and aging markets, the two largest health problem areas. AMRA is a spin-off company from CMIV in Linköping.

1.5 billion people in the world has overweight or obesity and it’s well known today that too much abdominal fat is dangerous and increases the risk for many diseases, but still there are no accurate and cost effective fat measurement tools available.

AMRA has developed such a tool for automatic measurement of both fat and muscle volumes, based upon a short; 6 minutes scan in a MR scanner

We can then build a 3D model of the human body where it’s possible to measure the amount of fat or muscle volume in every pixel (voxel since it’s 3D) It’s then easy for us to automatically measure the area of interest, e.g. the amount of dangerous adipose fat or the muscle volume in the legs. With this method it’s easy to do comparisons of muscles before and after a rehabilitation program or fat volume after a life style change.

Our tool is 15-20 times quicker compare to current methods and much more accurate.

Together with General Electric we have done successful studies in UK and GE are now introducing AMRA to the key opinion leaders in the obesity area who will test our products.

AMRAs goal is to develop a number of SW applications for different clinical usage. We expect that AMRA obesity application will be needed in most hospitals in the world.

Our short-term strategy is to approach the research market with a Cloud based analysis service model. We are in negotiations with our first paying customer who would like to do 100.000 analyses. This will be an excellent way to finance our company, to get study data for CE/FDA certification and to establish AMRA as the standard for fat and muscle measurement.

We are looking for financing to build up our Cloud based analysis services.

Bone Index Finland Ltd. provides patented, reliable and cost effective solution for the growing need of osteoporosis diagnostics at primary healthcare.

Quality and safety are essential part of our business. Bone Index Finland has ISO 13485 certified Quality System as a medical device manufacturer. Products manufactured by us fulfill the requirements of Medical Device Directive (MDD 93/42/EEC).

It is estimated that over 75% of osteoporotic patients are not diagnosed nor receive treatment for their condition because the diagnostics is done in special healthcare. Our solution to fight this problem, Bindex®, is validated against prevailing gold standard in diagnostics (axial DXA) at special healthcare by using international guidelines. Therefore Bindex® results are comparable to axial DXA.

By using the world’s first pocket size instrument for bone densitometry, Bindex®, the osteoporosis can be diagnosed wherever you want!

Cognuse is developing solutions for the mental healthcare industry.

Our core product platform CognuseManager is an evidence-based patient-centric tool for cognitive rehabilitation in the executive functions domain. It allows TBI and stroke patients to continue their rehabilitation processes in the home setting on most modern devices with a touch screen and gives the therapist an opportunity to monitor their progress in real-time and adjust the training plans, when necessary.

While the initial set of exercises focused on real-life tasks, we are now expanding into other cognitive domains to provide a full suite of services for the rehabilitation flow.

Our customers include hospitals, clinics, independent professionals and home users in neuropsychological rehabilitation, mental healthcare and other related sectors.

Fluence Therapeutics is commercializing photodynamic therapy for the treatment of psoriasis and other skin diseases.

We have successfully completed Phase Ia studies and are seeking funding for the completion of a Phase Ib/IIa proof of concept study in Tampere, Finland.

Current therapies are not adequate for the treatment of difficult cases of psoriasis.  Current light therapies use UV light, which is a known carcinogen, requires many treatments and results in premature photoaging.  Systemic pharmaceuticals globally suppress the immune system, resulting in increased rates of infection and certain kinds of cancers. 

Our therapy uses a novel photosensitizer which is activated by harmless red light and, unlike ALA PDT, does not result in pain or residual photosensitivity.  It can treat multiple, large lesions simultaneously.  It is totally inert unless activated by visible red light.  When activated, it preferentially kills activated t cells over other skin cells.

Founded in 2000, Nexstim is a medical device company developing non-invasive, image-guided transcranial magnetic stimulation (TMS) for brain diagnostics and therapy. Diagnostic applications have been designed for perioperative procedures of tumor and epilepsy surgery as well as stroke rehabilitation screening. Therapeutic applications include but are not limited to stroke rehabilitation and drug resistive depression treatment.

Nexstim Oy headquarters and international operations are located in Helsinki, Finland. Nexstim Inc., United States headquarters is based out of Alpharetta, GA and provides sales, service, support, and marketing for North America.

SuperECG has developed the HeartBug, an affordable and reliable ECG device for the consumers.

With the help of the SuperECG HeartBug and an online analysis service anyone can conduct a cardiac assessment that used to always require a visit to a clinic. The heartBug records the heart’s electrical activity for up to 24 hours and the advanced cardiac analysis system produces a report. The extensive report points out possible findings indicating arrhythmia, as well as the effect of physical exercise on cardiac rhythm.

The technology applied in the device and the analysis software has previously been developed by the parent company RemoteA for several years.